Interaction between high dose Rifampicin and Efavirenz in pulmonary tuberculosis and HIV co-infection – ANRS12292 Rifavirenz trial

Maryline Bonnet, Epicentre, on behalf of IRD UMI 233 TransVIHMI - UM – INSERM U1175, France

Background
Ongoing trials are evaluating high-dose rifampicin (R) regimens to shorten tuberculosis (TB) treatment duration. The risk of drug interaction with some antiretroviral precludes the inclusion of HIV-infected patients. We assessed the effect of high-dose R on the efavirenz (EFV) metabolism in co-infected patients.

Methods
RIFAVIRENZ was a phase-2, randomized, open-label trial conducted in Uganda between 2014 and 2017. Pulmonary TB and antiretroviral therapy (ART)-naïve patients were randomized to 2-study regimens (SR) using high-dose R (20mg/Kg) with ART initiation 2-4 weeks later with 600mg/day (SR1) or 800mg/day (SR2) EFV; or to 1-control regimen (CR) using R10mg/Kg and EFV600mg/day. At 8 weeks, all patients were switched to standard R and EFV doses. All patients had intensive pharmacokinetic sampling 4 weeks after EFV-R co-administration, and 4 weeks after R discontinuation. HIV and TB treatment response and safety were monitored.

Preliminary Results
Of 97 included patients (SR1: 31; SR2: 33; CR: 33), 26.8% were females and median age, weight and CD4 count were 33 years, 53.6 kg and 141 cells/L, respectively.

Under R, the median of the EFV minimum concentration (C24) was 1188, 1064 and 1078ng/mL for SR1 (N=27), SR2 (N=30) and CR (N=28), respectively. Five (18.5%), 6 (20.0%) and 8 (28.6%) patients had C24 < 750ng/mL. At 12 weeks post-ART initiation, 92.9%, 83.9% and 89.7% of patients had HIV viral load < 400 copies/mL. Week 8 TB culture conversion was 88.5% (SR1), 88.9% (SR2) and 90.3% (CR). During first 8 weeks, 6 (2 per arm) and 4 patients (SR1: 1; SR2: 2; CR: 1) had transaminase increase > grade 3 and neuropsychiatric events > grade 2, respectively.

Conclusions
Doubling the R dose does not seem to affect the EFV concentrations. These preliminary results need confirmation with the comparison of the EFV pharmacokinetics parameters with and without R.

Trial registration number: NCT01986543.

Trials evaluating high-dose rifampicin short regimens exclude HIV-infected patients due to risk of drug interaction with antiretroviral. Based on the preliminary RIFAVIRENZ trial results, doubling the rifampicin dose does not seem to affect the efavirenz concentrations.

These abstracts are not to be quoted for publication